GlassScriptPhysician profile
Nicholas A Maruniak
NPI 1235190356
$2,226.28
in general payments reported to CMS, 2019-2025
20 companies · $996 in 2025
The $996 reported for 2025 was more than what 88% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $134 · 2021: $174 · 2022: $110 · 2023: $247 · 2024: $253 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $379.23 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $378.10 | 2021-2025 | Prolaris |
| Astrazeneca Pharmaceuticals LP | $289.55 | 2019-2020 | |
| Astellas Pharma US INC | $190.22 | 2019-2025 | Myrbetriq, Xtandi |
| Sumitomo Pharma America, INC. | $182.52 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $144.22 | 2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $133.60 | 2021-2025 | Provenge |
| Novartis Pharmaceuticals Corporation | $103.95 | 2024-2025 | |
| Immunitybio, INC. | $72.24 | 2024-2025 | |
| Tolmar, INC. | $64.63 | 2023-2025 | Jatenzo, Eligard |
| Urogen Pharma, INC. | $56.66 | 2022-2025 | |
| Telix Pharmaceuticals | $46.54 | 2023-2024 | Illuccix |
| Cook Medical LLC | $30.15 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $28.88 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $27.51 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $26.49 | 2025 | |
| 180 Medical, INC. | $22.65 | 2021 | |
| Illumina, INC. | $20.47 | 2025 | Oncology Testing |
| Blue Earth Diagnostics | $15.78 | 2025 | Posluma |
| Metuchen Pharmaceuticals | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Maruniak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.